GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Consun Pharmaceutical Group Ltd (HKSE:01681) » Definitions » Cash, Cash Equivalents, Marketable Securities

Consun Pharmaceutical Group (HKSE:01681) Cash, Cash Equivalents, Marketable Securities : HK$3,855 Mil (As of Jun. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Consun Pharmaceutical Group Cash, Cash Equivalents, Marketable Securities?

Consun Pharmaceutical Group's quarterly cash, cash equivalents, marketable securities increased from Jun. 2023 (HK$3,458.75 Mil) to Dec. 2023 (HK$3,919.23 Mil) but then stayed the same from Dec. 2023 (HK$3,919.23 Mil) to Jun. 2024 (HK$3,855.35 Mil).

Consun Pharmaceutical Group's annual cash, cash equivalents, marketable securities increased from Dec. 2021 (HK$2,970.95 Mil) to Dec. 2022 (HK$3,394.08 Mil) and increased from Dec. 2022 (HK$3,394.08 Mil) to Dec. 2023 (HK$3,919.23 Mil).


Consun Pharmaceutical Group Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Consun Pharmaceutical Group's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Consun Pharmaceutical Group Cash, Cash Equivalents, Marketable Securities Chart

Consun Pharmaceutical Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash, Cash Equivalents, Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,539.19 2,300.06 2,970.95 3,394.08 3,919.23

Consun Pharmaceutical Group Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,872.62 3,394.08 3,458.75 3,919.23 3,855.35

Consun Pharmaceutical Group Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


Consun Pharmaceutical Group  (HKSE:01681) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Consun Pharmaceutical Group Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Consun Pharmaceutical Group's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


Consun Pharmaceutical Group Business Description

Industry
Traded in Other Exchanges
Address
71, Dongpeng Avenue, Eastern section, Guangzhou Economic and Technological Development, Guangzhou, CHN
Consun Pharmaceutical Group Ltd is a biotechnology company with a modern pharmaceutical enterprise that integrates R&D, production, and marketing. The company has two reportable segments: the Consun pharmaceutical segment, which is the key revenue driver, and makes and sells modern Chinese medicines and medical contrast medium, and the Yulin pharmaceutical segment, which manufactures and sells traditional Chinese medicines. Consun derives revenue from kidney medicines, contrast mediums, orthopedics medicines, dermatologic medicines, hepatobiliary medicines, medicines for women and children, and others.
Executives
Double Grace International Limited 2101 Beneficial owner
Li Qian 2101 Beneficial owner
An Yubao 2101 Beneficial owner
Central Success Developments Limited 2101 Beneficial owner
Aali Resources Limited 2201 Interest of corporation controlled by you
Bos Trustee Limited 2301 Trustee
Zhang Lihua 2202 Interest of your spouse
An Meng 2101 Beneficial owner
Bos Trustee Limited As Trustee 2201 Interest of corporation controlled by you

Consun Pharmaceutical Group Headlines

No Headlines